Prospects for genetic modulation of corneal graft survival

Eye

Volumn 23, Issue 10, 2009, Pages 1904-1909

  Williams, K A ^a   Brereton, H M ^a   Coster, D J ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

Corneal transplantation; Gene therapy; Therapeutic transgenes; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; ENDOSTATIN; ENDOSTATIN KRINGLE 5 FUSION PROTEIN; HYBRID PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 4; LENTIVIRUS VECTOR; NERVE GROWTH FACTOR; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG;

APOPTOSIS; CONFERENCE PAPER; CORNEA GRAFT REJECTION; CORNEA TRANSPLANTATION; DRUG SAFETY; GENE EXPRESSION; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KRINGLE DOMAIN; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; RNA TRANSLATION; SPECIES DIFFERENCE; SURVIVAL TIME; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; CORNEAL DISEASES; CORNEAL TRANSPLANTATION; DISEASE MODELS, ANIMAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GRAFT SURVIVAL; HUMANS;

EID: 70350155086     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.378     Document Type: Conference Paper

References (52)

1. Williams KA, Esterman AJ, Bartlett C, Holland H, Hornsby NB, Coster DJ, on behalf of all contributors to the Australian Corneal Graft Registry. How effective is penetrating corneal transplantation? Factors influencing long-term outcome in multivariate analysis. Transplantation 2006; 81: 896-901.
2. Niederkorn JY. The immune privilege of corneal grafts. J Leukoc Biol 2003; 74: 167-171.
3. George AJ, Larkin DF. Corneal transplantation: the forgotten graft. Am J Transplant 2004; 4: 678-685.
4. Coster DJ, Williams KA. The impact of corneal allograft rejection on the long-term outcome of corneal transplantation. Am J Ophthalmol 2005; 140: 1112-1122.
5. Williams KA, Coster DJ. The immunobiology of corneal transplantation. Transplantation 2007; 84: 806-813.
6. Coster DJ, Williams KA. Management of high-risk corneal grafts. Eye 2003; 17: 996-1002.
7. The Collaborative Corneal Transplantation Studies Research Group. The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol 1992; 110: 1392-1403.
8. Khaireddin R, Wachtlin J, Hopfenmüller W, Hoffmann F. HLA-A, HLA-B and HLA-DR matching reduces the rate of corneal allograft rejection. Graefes Arch Clin Exp Ophthalmol 2003; 241: 1020-1028.
9. George AJ, Arancibia-Cárcamo CV, Awad HM, Comer RM, Fehevari Z, King WJ et al. Gene delivery to the corneal endothelium. Am J Respir Crit Care Med 2000; 162: S194-S200.
10. Williams KA, Jessup CF, Coster DJ. Gene therapy approaches to prolonging corneal allograft survival. Expert Opin Biol Ther 2004; 4: 1059-1071.
11. Williams KA, Coster DJ. Penetrating corneal transplantation in the inbred rat: a new model. Invest Ophthalmol Vis Sci 1985; 26: 23-30.
12. Williams KA, Standfield SD, Mills RA, Takano T, Larkin DF, Krishnan R et al. A new model of orthotopic penetrating corneal transplantation in the sheep: graft survival, phenotypes of infiltrating cells and local cytokine production. Aust NZ J Ophthalmol 1999; 27: 127-135.
13. She SC, Steahly LP, Moticka EJ. A method for performing full-thickness, orthotopic, penetrating keratoplasty in the mouse. Ophthalmic Surg 1990; 21: 781-785.
14. Khodadoust AA. Penetrating keratoplasty in the rabbit. Am J Ophthalmol 1968; 66: 899-905.
15. Tavandzi U, Procházka R, Usvald D, Hlucílová J, Vitásková M, Motlík J et al. A new model of corneal transplantation in the miniature pig: efficacy of immunosuppressive treatment. Transplantation 2007; 83: 1401-1403.
16. Klebe S, Sykes PJ, Coster DJ, Krishnan R, Williams KA. Prolongation of sheep corneal allograft survival by transfer of the gene encoding ovine interleukin 10. Transplantation 2001; 71: 1214-1220.
17. König Merediz SA, Zhang EP, Wittig B, Hoffmann F. Ballistic transfer of minimalistic immunologically defined expression constructs for IL4 and CTLA4 into the corneal epithelium in mice after orthotopic corneal allograft transplantation. Graefes Arch Clin Exp Ophthalmol 2000; 238: 701-707.
18. Zhang EP, Franke J, Schroff M, Junghans C, Wittig B, Hoffmann F. Ballistic CTLA4 and IL-4 gene transfer into the lower lid prolongs orthotopic corneal graft survival in mice. Graefes Arch Clin Exp Ophthalmol 2003; 241: 921-926.
19. Pleyer U, Bertelmann E, Rieck P, Hartmann C, Volk HD, Ritter T. Survival of corneal allografts following adenovirusmediated gene transfer of interleukin-4. Graefes Arch Clin Exp Ophthalmol 2002; 238: 531-536.
20. Rayner SA, Larkin DF, George AJ. TNF receptor secretion after ex vivo adenoviral gene transfer to cornea and effect on in vivo graft survival. Invest Ophthalmol Vis Sci 2001; 42: 1568-1573.
21. Klebe S, Coster DJ, Sykes PJ, Scheerlinck J-P, Krishnan R, Williams KA. Prolongation of sheep corneal allograft survival by transfer of the gene encoding ovine interleukinp 12 p40, but not interleukin 4 to donor corneal endothelium. J Immunol 2005; 175: 2219-2226.
22. Murthy RC, McFarland TJ, Yoken J, Chen S, Barone C, Burke D et al. Corneal transduction to inhibit angiogenesis and graft failure. Invest Ophthalmol Vis Sci 2003; 44: 1837-1842.
23. Comer RM, King WJ, Ardjomand N, Theoharis S, George AJ, Larkin DF. Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival. Invest Ophthalmol Vis Sci 2002; 43: 1095-1103.
24. Gong N, Pleyer U, Vogt K, Anegon I, Flügel A, Volk HD et al. Local overexpression of nerve growth factor in rat corneal transplants improves allograft survival. Invest Ophthalmol Vis Sci 2007; 48: 1043-1052.
25. Barcia RN, Dana MR, Kazlauskas A. Corneal graft rejection is accompanied by apoptosis of the endothelium and is prevented by gene therapy with bcl-xL. Am J Transplant 2007; 7: 2082-2089.
26. Beutelspacher SC, Pillai R, Watson MP, Tan PH, Tsang J, McClure MO et al. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur J Immunol 2006; 36: 690-700.
27. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006; 108: 1435-1440.
28. Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006; 6: 876-883.
29. Mellor AL, Chandler P, Baban B, Hansen AM, Marshall B, Pihkala J et al. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4- mediated induction of indoleamine 2,3 dioxygenase. Int Immunol 2004; 16: 1391-1401.
30. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol 2007; 7: 817-823.
31. Ryu YH, Kim JC. Expression of indoleamine 2,3-dioxygenase in human corneal cells as a local immunosuppressive factor. Invest Ophthalmol Vis Sci 2007; 48: 4148-4152.
32. Ergün S, Kilic N, Wurmbach JH, Ebrahimnejad A, Fernando M, Sevinc S et al. Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. Angiogenesis 2001; 4: 193-206.
33. Nguyen TM, Subramanian IV, Kelekar A, Ramakrishnan S. Kringle 5 of human plasminogen, an angiogenesis inhibitor, induces both autophagy and apoptotic death in endothelial cells. Blood 2007; 109: 4793-4802.
34. Kim R. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun 2005; 333: 336-343.
35. Pleyer U, Groth D, Hinz B, Keil O, Bertelmann E, Rieck P et al. Efficiency and toxicity of liposome-mediated gene transfer to corneal endothelial cells. Exp Eye Res 2001; 73: 1-7.
36. Collins L, Fabre JW. A synthetic peptide vector system for optimal gene delivery to corneal endothelium. J Gene Med 2004; 6: 185-194.
37. Bennett J. Immune response following intraocular delivery of recombinant viral vectors. Gene Therapy 2003; 10: 977-982.
38. Ritter T, Gong N, Pleyer U. Is ex vivo adenovirus mediated gene transfer a therapeutic option for the treatment of corneal diseases? Br J Ophthalmol 2005; 89: 648-649.
39. Grieger JC, Samulski RJ. Adeno-associated virus as a gene therapy vector: vector development, production and clinical applications. Adv Biochem Eng Biotechnol 2005; 99: 119-145.
40. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358: 2231-2239.
41. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003; 4: 346-358.
42. Smith RH. Adeno-associated virus integration: virus versus vector. Gene Therapy 2008; 15: 817-822.
43. Buchschacher GL, Wong-Staal F. Development of lentiviral vectors for gene therapy for human diseases. Blood 2000; 95: 2499-2504.
44. Wang X, Appukuttan B, Ott S, Patel R, Irvine J, Song J et al. Efficient and sustained transgene expression in human corneal cells mediated by a lentiviral vector. Gene Therapy 2000; 7: 196-200.
45. Takahashi K, Luo T, Saishin Y, Saishin Y, Sung J, Hackett S et al. Sustained transduction of ocular cells with a bovine immunodeficiency viral vector. Hum Gene Ther 2002; 13: 1305-1316.
46. Bainbridge JW, Stephens C, Parsley K, Demaison C, Halfyard A, Thrasher AJ et al. In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium. Gene Therapy 2001; 8: 1665-1668.
47. Parker DGA, Kaufmann C, Brereton HM, Anson DS, Francis-Staite L, Jessup CF et al. Lentivirus-mediated gene transfer to the rat, ovine and human cornea. Gene Therapy 2007; 14: 760-767.
48. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999; 286: 2244-2245.
49. Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL et al. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther 2002; 13: 15-63. (Pubitemid 34075172)
50. Kaiser J. Clinical trials. Gene transfer an unlikely contributor to patient's death. Science 2007; 318: 1535.
51. Bushman FD. Retroviral integration and human gene therapy. J Clin Invest 2007; 117: 2083-2086.
52. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.